UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 15,142 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 189,220 shares of the specialty pharmaceutical company's stock after buying an additional 15,142 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.31% of Jazz Pharmaceuticals worth $23,302,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $25,000. Quadrant Capital Group LLC lifted its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Allianz SE bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $29,000. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after acquiring an additional 130 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the sale, the chief executive officer now owns 464,058 shares in the company, valued at approximately $66,940,366.50. This represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Seamus Mulligan bought 1,621 shares of the business's stock in a transaction on Monday, May 12th. The stock was bought at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the purchase, the director now directly owns 101,621 shares of the company's stock, valued at approximately $10,466,963. This trade represents a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 19,623 shares of company stock worth $2,710,591 over the last three months. 4.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have commented on JAZZ. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Barclays restated an "overweight" rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Piper Sandler reissued an "overweight" rating and set a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded up $0.02 during mid-day trading on Friday, reaching $108.28. The company had a trading volume of 977,559 shares, compared to its average volume of 838,951. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $6.68 billion, a P/E ratio of 15.25, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The stock's 50-day simple moving average is $109.72 and its two-hundred day simple moving average is $121.35.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company's revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.68 EPS. Research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.